title: Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients.
abstract: OBJECTIVE
  To investigate the reciprocal inhibitory effects of hepatitis B virus (HBV)/hepatitis C virus (HCV)/hepatitis D virus (HDV) infections in naive and previously antiretroviral-experienced HIV-positive patients.
  
  
  METHODS
  This retrospective study involved 72 consecutive patients of the Italian Cohort Naive Antiretroviral cohort: 21 coinfected with HBV/HCV (group 1BC), 18 infected with HBV (group 2B), and 33 infected with HCV (group 3C).
  
  
  METHODS
  Viral interference between HBV and HCV was assessed by means of the qualitative detection, quantification, and genotyping of each virus; HDV infection was assessed by means of genomic amplification.
  
  
  RESULTS
  Univariate analysis showed that HBV DNA was less frequently detected in group 1BC than in group 2B (16 of 21 vs 18 of 18; P = 0.02), their HBV load was significantly lower (median 3.9 vs 5.4 log10 HBV DNA copies/mL; P = 0.002), and they more frequently carried HBV genotype D (12 of 13 vs 4 of 11; P = 0.0071). HCV RNA was less frequently detected in group 1BC than in group 3C (12 of 21 vs 33 of 33; P < 0.0001), and HDV RNA was more frequently detected in group 1BC than in group 2B (9 of 21 vs 2 of 18; P = 0.028). Multivariate analysis of the HBV-infected subjects showed that the risk of HCV coinfection was associated with older age [relative risk 0.28, 95% confidence interval (CI): 0.09 to 0.90; P = 0.033 for every 10 years older] and intravenous drug use (relative risk 73, 95% CI: 2.4 to >999.999; P = 0.013). The only predictor of HBV coinfection in HCV-infected individuals was a lower HCV load (relative risk 0.30, 95% CI: 0.11 to 0.79 for every additional log10 HCV RNA; P = 0.015).
  
  
  CONCLUSIONS
  HBV and HCV showed alternative dominant replication in the I.Co.N.A. cohort, with HBV having a more unfavorable effect on HCV replication.
authors: Department of Infectious Diseases, San Raffaele, Scientific Institute, Milan, Italy. morsica.giulia@hsr.it
authors: Giulia
authors: G
authors: Morsica
authors: Sabrina
authors: S
authors: Bagaglio
authors: Paola
authors: P
authors: Cicconi
authors: Maria R
authors: MR
authors: Capobianchi
authors: Giampietro
authors: G
authors: Pellizzer
authors: Pietro
authors: P
authors: Caramello
authors: Anna
authors: A
authors: Orani
authors: Cristina
authors: C
authors: Moioli
authors: Giuliano
authors: G
authors: Rizzardini
authors: Caterina
authors: C
authors: Uberti-Foppa
authors: Massimo
authors: M
authors: Puoti
authors: Antonella D'Arminio
authors: AD
authors: Monforte
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D001483:Base Sequence; D015331:Cohort Studies; D017931:DNA Primers / Q000235:genetics; D004279:DNA, Viral / Q000097:blood; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000821:virology; D016174:Hepacivirus / Q000235:genetics; D006509:Hepatitis B / Q000150:complications* / Q000821:virology; D006515:Hepatitis B virus / Q000235:genetics; D006526:Hepatitis C / Q000150:complications* / Q000821:virology; D003699:Hepatitis D / Q000150:complications* / Q000821:virology; D003698:Hepatitis Delta Virus / Q000235:genetics; D006801:Humans; D007558:Italy; D008297:Male; D009154:Mutation; D012367:RNA, Viral / Q000097:blood / Q000235:genetics; D012189:Retrospective Studies; D012307:Risk Factors; D014762:Viral Interference
chemical_list: D019380:Anti-HIV Agents; D017931:DNA Primers; D004279:DNA, Viral; D012367:RNA, Viral